Loading
Altimmune, Inc. Stock: price and insider trades · United States
1 insider bought €38k of shares over the last 90 days, the latest by Durso Jerome Benedict, filed 13 Aug 2026.
Altimmune, Inc.: what insiders have been doing
Altimmune, Inc., founded in 1997, is a Healthcare & Pharma company based in Gaithersburg, United States. Its directors and officers file their transactions with SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 33 filings came from 11 insiders.
Only purchases show up on the open market, 11 purchases in all worth €318k, filed by 6 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €61k from Durso Jerome Benedict, disclosed on 9 March 2026. Among those who bought: 5 senior executives, 1 finance chief and 1 chief executive.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 33 filings, this issuer sits above that mark. Looking back to 2021, when coverage begins, insiders filed 19 purchases and 6 sales. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -88.1 m USD.
Within a 30-day window, 9 purchases overlapped with buying by a second insider. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 13 August 2026, 66 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
137
Thresholds
n/a
Buy Volume
€498,709
19 ops. · all time
Sell Volume
€977,356
6 ops. · all time
Who traded when
BuySaleJerome Benedict Durso4 buys
Gregory L. Weaver3 buys
Catherine A. Sohn2 buys
John Gill2 buys
Diane Jorkasky1 buy
Wayne Pisano1 buy
Since the insiders bought
- -25.2%Entry US$2.94 · Close 16 Oct 2026 US$2.20
- -8.9%Entry US$3.38 · Close at T+90 US$3.08
- -34.1%Entry US$3.34 · Close 16 Oct 2026 US$2.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Altimmune, Inc. Strong Buy (bullish), based on 9 analysts. Average price target: US$17.11.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.20
Analyst consensus
9 analystsStrong buy
US$11.00Target US$17.11(+678%)US$28.00
Income statement
RevenueUS$41k
EBITDA-US$87M-212259% margin
Net income-US$88.1M-214861.0% margin
Valuation
PER (forward)-3.3x
P/Book0.9x
Beta0.06
Balance sheet & cash
Market capUS$427.9M
Total debtUS$35.7M
Free Cash Flow-US$67.5M
Debt / Equity8%
Profitability & ownership
ROE-28.9%
ROA-17.2%
% insiders0.4%
% institutions78.0%
Last declaration on 5 October 2026
Declarations137 total
14,475 shares0Common Stock, par value $0.0001SEC:0001251779-26-000011:0
4,379 shares@ US$2.760.0023% mcap10.2% of flowCommon Stock, par value $0.0001SEC:0001251779-26-000011:1
37,500 shares0Common Stock, par value $0.0001SEC:0001802615-26-000002:0
12,679 shares@ US$2.760.0065% mcap100.0% of flowCommon Stock, par value $0.0001SEC:0001802615-26-000002:1
24,000 shares0Common Stock, par value $0.0001SEC:0001595064-26-000002:0
6,826 shares@ US$3.240.0035% mcap100.0% of flowCommon Stock, par value $0.0001SEC:0001595064-26-000002:1
15,000 shares@ US$2.950.0070% mcap20.8% of flowCommon Stock, par value $0.0001SEC:0001698665-26-000007:0
Canonical exit: 11 Nov 2026 (T+90)
1,753 shares@ US$2.4140.0007% mcap3.9% of flowCommon Stock, par value $0.0001SEC:0001251779-26-000009:0
875 shares@ US$2.4140.0003% mcap0.3% of flowCommon Stock, par value $0.0001SEC:0001705905-26-000010:0
15,000 shares@ US$3.1422.1% of flowCommon Stock, par value $0.0001SEC:0001698665-26-000005:0
Canonical exit: 30 Jun 2026 (T+90)
10,000 shares@ US$3.149929.0% of flowCommon Stock, par value $0.0001SEC:0001251779-26-000007:0
Canonical exit: 30 Jun 2026 (T+90)
20,000 shares@ US$3.539533.1% of flowCommon Stock, par value $0.0001SEC:0001698665-26-000003:0
Canonical exit: 4 Jun 2026 (T+90)
5,000 shares@ US$3.5416.2% of flowCommon Stock, par value $0.0001SEC:0001251779-26-000005:0
Canonical exit: 4 Jun 2026 (T+90)
9,275 shares0Common Stock, par value $0.0001SEC:0001705905-26-000006:0
4,571 shares@ US$3.0712.5% of flowCommon Stock, par value $0.0001SEC:0001960780-26-000008:0
26,775 shares0Common Stock, par value $0.0001SEC:0001515813-26-000006:0
15,850 shares0Common Stock, par value $0.0001SEC:0001960780-26-000006:0
15,850 shares0Common Stock, par value $0.0001SEC:0001705905-26-000004:0
41,200 shares0Common Stock, par value $0.0001SEC:0001515813-26-000004:0
17,984 shares@ US$5.508.3% of flowCommon Stock, par value $0.0001SEC:0001515813-26-000002:1
4,373 shares@ US$5.503.3% of flowCommon Stock, par value $0.0001SEC:0001705905-26-000002:1
3,855 shares@ US$5.5019.2% of flowCommon Stock, par value $0.0001SEC:0001960780-26-000004:1
42,050 shares0Common Stock, par value $0.0001SEC:0001515813-26-000002:0
14,600 shares0Common Stock, par value $0.0001SEC:0001705905-26-000002:0
25 of 137 declarations
About Altimmune, Inc.
Altimmune, Inc. is a U.S.-listed biotechnology company trading on the Nasdaq (United States) and focused on developing therapies for serious liver diseases. The company is a late clinical-stage biopharmaceutical developer whose strategy is now centered on pemvidutide, its lead candidate, which is being advanced across metabolic and liver-related indications with meaningful unmet medical need. Altimmune is headquartered in Gaithersburg, Maryland, placing it in one of the key biopharma hubs on the U.S. East Coast. ([ir.altimmune.com](https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-fourth-quarter-and-full-year-2025-financial))
From a historical perspective, Altimmune was founded in 1997. The company’s current corporate form reflects a major strategic evolution, including the merger with PharmAthene completed in 2017, after which the combined entity began trading as Altimmune, Inc. on Nasdaq under ticker ALT. Over time, the business has shifted from a broader vaccine/immunotherapeutics profile toward a narrower, higher-conviction clinical focus built around pemvidutide and the liver-disease opportunity set. ([stockanalysis.com](https://stockanalysis.com/stocks/alt/company/?utm_source=openai))
Read moreShow less
Operationally, Altimmune is now highly concentrated on pemvidutide development in MASH (metabolic dysfunction-associated steatohepatitis), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Management disclosed that pemvidutide has received FDA Breakthrough Therapy Designation in MASH, that the global PERFORMA Phase 3 MASH trial is planned for initiation in the second half of 2026, and that topline data from the RECLAIM Phase 2 AUD study are expected in the third quarter of 2026. The RESTORE Phase 2 ALD trial is also progressing, making the company’s 2026 calendar unusually catalyst-rich for a single-asset biotech. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000037/alt-20260513xex99d1.htm))
In competitive terms, Altimmune remains a relatively small player versus large pharmaceutical companies and better-capitalized biotech peers targeting liver and metabolic disease. Its investment case rests on whether pemvidutide can demonstrate a differentiated efficacy/tolerability profile and whether that profile can translate into clinical, regulatory, and ultimately commercial value. The company itself has emphasized pemvidutide’s potential to address critical unmet needs, especially in MASH, where approved therapies have not eliminated substantial room for differentiation. ([ir.altimmune.com](https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-fourth-quarter-and-full-year-2025-financial))
Recent developments are important for investors. In April 2026, Altimmune closed an oversubscribed public offering that generated gross proceeds of $225 million, explicitly framed as funding for the Phase 3 MASH program and extending cash runway through the anticipated 52-week readout. In its first-quarter 2026 update, the company reported approximately $535 million in cash, cash equivalents and short-term investments as of April 30, 2026. For investors tracking SEC Form 4 insider transactions, these financing and governance disclosures, alongside insider filings, make Altimmune a closely watched small-cap biotech name with significant event-driven potential. ([ir.altimmune.com](https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-closing-225-million-oversubscribed-public))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
